A company reports an operating loss of more than $10 billion in a single quarter. Its stock sits within striking distance of a 52-week high. Those two facts should not coexist without a very good explanation, and Gilead Sciences has one, though it is more complicated than the headlines suggest. The question worth asking in August 2026 is whether the explanation fully justifies the price.
Gilead spent the early 2020s as a reliable, slightly boring cash machine, built on HIV antivirals and a hepatitis franchise that was slowly shrinking. Then it went shopping, aggressively and expensively, betting that oncology and cell therapy could replace what hepatitis C was losing. That bet is still being scored, and the score depends heavily on which accounting line a reader chooses to read.
The story, briefly
The filed numbers show a business whose core HIV engine is growing faster than it has in years, with operating cash flow running at a pace that would cover the entire company’s annual revenue in roughly a decade. The price sits at the 96th percentile of Gilead’s own decade-long range, meaning the market is paying a premium it has almost never paid before. The open question is whether three large acquisitions completed in 2026, each still unproven, justify that premium, or whether the math of the base business alone does.
Claim one: “The operating loss means Gilead is in trouble”
The 10-Q for the quarter ended June 30, 2026 shows a GAAP operating loss of $10.4 billion for Q2 2026. That number is real. It is also almost entirely explained by a single accounting entry: $11.1 billion in acquired in-process research and development charges, the cost of booking the future drug pipelines from three acquisitions, Arcellx, Tubulis, and Ouro Medicines, as an immediate expense rather than spreading it over years.
Strip that charge out, and the non-GAAP operating margin for the quarter was roughly 49%. Think of it this way: for every dollar Gilead collected from selling drugs in Q2, about 49 cents was left after paying the bills of actually running the business. That is not a company in distress. The August 4 earnings release also shows $3.6 billion in operating cash flow generated in that single quarter, more than the company holds in cash on hand. Cash flow is what a business actually collects; the accounting loss is what the rulebook requires it to record. Both are true. Only one reflects whether the lights stay on.
The filed history adds context. The 10-K for fiscal year 2024 shows a razor-thin net margin, again because of large acquisition-related charges. The 10-K for fiscal year 2025 then shows a healthy net margin once those charges cleared. The pattern is consistent: Gilead buys something, takes a painful accounting hit, then the underlying business resurfaces. The risk is not that the business is broken. The risk is that the things it bought do not work.
Claim two: “HIV growth is the whole story”
HIV is genuinely the engine. Q2 2026 HIV sales reached $5.7 billion, up 12% from a year earlier, driven by Biktarvy and a prevention business that more than doubled year-over-year to exceed a billion dollars in the quarter. Gilead raised its full-year HIV growth forecast to the high single digits, up from its prior guidance. For a franchise of this size, that is meaningful acceleration, not a rounding error.
But the claim that HIV is the whole story misses what is happening at the edges, in both directions. Trodelvy, the oncology drug acquired with Immunomedics in 2020, posted strong double-digit sales growth in Q2 2026, and the FDA approved it in June 2026 for a new indication in first-line metastatic triple-negative breast cancer. That approval matters because it opens a larger patient population. Meanwhile, the cell therapy segment fell by a double-digit percentage in Q2, squeezed by competition. And Veklury, the COVID antiviral that briefly made Gilead a household name, is now guided to roughly half its prior-year revenue because hospitalizations have dropped.
The honest picture is a business with one dominant, growing franchise, one oncology asset gaining real traction, one cell therapy franchise losing ground, and a COVID tailwind that has nearly vanished. That is more complicated than “HIV is everything,” and the complications matter for anyone assessing whether the price is fair.
Claim three: “The valuation is reasonable given the growth”
This is the claim that deserves the most scrutiny, because the filed numbers and the market price are telling genuinely different stories. Our data shows Gilead’s price-to-sales ratio, the price paid per dollar of annual revenue, at 5.9 times, sitting at the 96th percentile of its own decade-long range. The decade median is 3.6 times. In plain terms: the market is paying a price for each dollar of Gilead’s sales that it has almost never paid before.
The P/E ratio is not useful right now because the acquisition charges have made trailing earnings negative. The more instructive figure is the EV/EBITDA of roughly 12 times, where EV is the total price to buy the whole company including its debt, and EBITDA is a rough proxy for operating cash generation. Twelve times is not extreme for a pharmaceutical company with durable franchises. But it sits alongside a price-to-sales multiple that implies the market expects revenue to grow substantially and margins to hold.
Zacks Research, as of August 19, 2026, puts the 2027 EPS consensus at $9.30. Erste Group Bank, in an August 5 report, lowered its own 2027 EPS estimate slightly to $9.57. At a price near $147, either figure would imply a forward earnings multiple well below the decade median. Third-party consensus estimates compiled by MarketBeat as of August 2026 reflect a range of analyst views; readers can weigh those against the conditional scenarios described here.
The filed record does not contradict that logic. It does not confirm it either. The three acquisitions completed in 2026 cost a combined fifteen billion dollars or more, and their pipeline assets have not yet generated commercial revenue. An FDA decision on the once-daily HIV tablet combining bictegravir and lenacapavir was expected by August 27, 2026, and a decision on the CAR T therapy anito-cel for multiple myeloma is expected by December 2026. Those decisions will either validate the spending or reopen the question of whether Gilead overpaid.
Reading the numbers
Q2 2026 total revenue: $7.8 billion, up 10% year-over-year. This is what Gilead collected from all sources in the April-to-June quarter. Ten percent growth on a base this large means the business added roughly the annual revenue of a mid-sized pharmaceutical company in a single year’s pace. Source: 10-Q, June 30, 2026.
Non-GAAP operating margin: approximately 49%. This is what remains of each dollar of drug sales after paying the costs of running the business, but before the acquisition accounting charges. A household analogy: if a family earned $100,000 and spent $51,000 on groceries, utilities, and the mortgage, they would have $49,000 left. Gilead’s core operations are generating that kind of surplus. Source: August 4, 2026 earnings release.
Price-to-sales ratio: 5.9 times, at the 96th percentile of the decade range. The decade median is 3.6 times. IF the P/S ratio were to revert to its own decade median and IF revenue held near current levels, the arithmetic would point to a price roughly 40% below current levels, all else equal. That gap represents the embedded growth assumption the market is currently pricing in. Source: our data, computed from SEC filings and market prices.
Full-year 2026 illustrative non-GAAP EPS guidance: $8.50 to $8.85. This excludes acquisition charges and financing costs. It is the number Gilead wants investors to use when thinking about underlying earning power. At today’s price, that implies a current-year multiple just below the decade median. Source: Q2 2026 prepared remarks, August 4, 2026.
Operating cash flow, Q2 2026: $3.6 billion. Cash flow is what actually arrived in the bank, not an accounting construct. Annualized, that pace would exceed half the company’s total annual revenue. That is the financial foundation the acquisitions are being built on. Source: 10-Q, June 30, 2026.
The math of the base business is genuinely strong. The mood, meaning what the market is currently paying, prices in a future where the acquisitions also work. Those are two separate bets, and the filings can only confirm the first one.
For the standing yardsticks on Gilead Sciences: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Gilead Sciences.
Sources
- Gilead 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Gilead 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Gilead 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
- Gilead Q2 2026 earnings release, August 4, 2026
- Gilead Q2 2026 prepared remarks, August 4, 2026
- Gilead Q2 2026 earnings call transcript (Seeking Alpha)
- Zacks Research 2027 EPS estimate, August 19, 2026 (MarketBeat)
- Erste Group Bank 2027 EPS estimate, August 5, 2026 (MarketBeat)
- Zacks on Gilead HIV portfolio, August 2026
- FDA NDA for bictegravir/lenacapavir, PDUFA date August 27, 2026
